Status:
COMPLETED
Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA213JP
Lead Sponsor:
Chugai Pharmaceutical
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
20-75 years
Phase:
PHASE3
Brief Summary
This is an open-label, extension, Phase III study to evaluate the long-term safety and efficacy of MRA in patients with RA who participated in Study MRA213JP.
Eligibility Criteria
Inclusion
- Inclusion criteria
- Either MRA or placebo was administered at least 3 times in the preceding study, and there were confirmed to be no problems with respect to safety.
- In the case of Patients whose participation in the current study was judged to be inappropriate because of problems in the preceding study with respect to safety, these Patients must have been in the methotrexate dose group in the preceding study.
- Exclusion criteria
- Administered drugs such as infliximab, etanercept, and leflunomide within 12 weeks before administration of the study drug
- Evaluated as belonging to Steinbrocker's class IV within 4 weeks before administration of the study drug
- Have not been registered by 3 months after the full code-breaking of the preceding study
- Were administered plasma exchange therapy between initiation of the preceding study and the initial administration in the current study
- Treated surgically (except for local surgery) within 4 weeks before administration of the study drug
Exclusion
Key Trial Info
Start Date :
June 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
115 Patients enrolled
Trial Details
Trial ID
NCT00144534
Start Date
June 1 2004
End Date
June 1 2009
Last Update
December 23 2009
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.